BIOMAT Database Logo BIOMAT Database Logo

[The interferon reaction of the leukocytes and the natural killer activity in patients with acute viral hepatitis B undergoing interferon treatment]. 1994

T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko

The interferon response of leukocytes (IRL) alpha and gamma as well as the functional activity of natural killers (NK) were studied in patients with the verified diagnosis of acute viral hepatitis B (AVH-B) treated with leukinferon (a preparation of natural interferon-alpha and cytokines) and reaferon (recombinant alpha 2 interferon). The effect of therapy with LF and RF in patients with AVH-B manifested by an increase in the functional activity of NK up to complete normalization after termination of the course of therapy. In the group of patients treated with LF as a result of therapy IRL-alpha increased by the end of the treatment and in the convalescence period. The observed activation of NK and the IF-alpha system under the effect of IF preparations in patients with AVH-B correlated with enhanced elimination of HBsAg.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003289 Convalescence The period of recovery following an illness. Convalescences
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
Natural killer activity in patients with acute viral hepatitis.
April 1986, Clinical and experimental immunology,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[Interferon in the treatment of acute viral hepatitis B].
January 1989, Terapevticheskii arkhiv,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[The interferon system and natural cytotoxicity functions in patients with acute viral hepatitis A and B].
January 1994, Terapevticheskii arkhiv,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[Natural killer cell activity and induction of alpha and gamma interferon in patients with Coxsackie B viral myocarditis].
December 1988, Zhonghua xin xue guan bing za zhi,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
Interleukin-2 and natural killer activity in acute type B hepatitis.
August 1991, Hepato-gastroenterology,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
Viral nucleotide changes in asymptomatic hepatitis B carriers undergoing interferon treatment.
April 1996, Alimentary pharmacology & therapeutics,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[Immediate hypersensitivity reaction in acute viral hepatitis A and B treated with interferon inducers].
January 1989, Sovetskaia meditsina,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[Reaction between leukocytes of patients affected with acute viral hepatitis and serum of recovered patients].
December 1971, Giornale di malattie infettive e parassitarie,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
Serum level of interferon alpha in patients with acute viral hepatitis B.
January 1998, Folia medica,
T D Golban, and S G Cheshik, and V P Kuznetsov, and D L Beliaev, and S V Grishchenko, and K M Morgunov, and A A Babaiants, and O E Polikushina, and S M Antonenko
[The interferon system in acute viral hepatitis B].
January 1987, Sovetskaia meditsina,
Copied contents to your clipboard!